Roivant reports first LISRAYA sales of $31.0 million and misses on Immunovant trial. Roivant reported $31.0 million in LISRAYA net product revenue in its first five weeks of launch, and a $0.27 per share net loss for the quarter ended September 30, 2026. By Yash Upadhyaya Key takeaways. * Roivant (ROIV) reported $31.0 million in LISRAYA net product revenue in its first five weeks of launch after U.S. approval in August 2026. The company reported a net loss of $191.6 million, or $0.27 per share, for the quarter ended September 30, 2026. Cash and marketable securities totaled $4.2 billion. Roivant (ROIV) reported $31.0 million in net product revenue from LISRAYA, its brepocitinib drug, in the first five weeks after its August 2026 U.S. launch. The net loss attributable to Roivant Sciences Ltd. was $191.6 million, or $0.27 per share, for the quarter ended September 30, 2026, versus $113.5 million, or $0.17 per share, a year earlier. Shares rose 2.9% premarket at 8:18 a.m. ET, from a $38.88 close. Trial and pipeline updates. IMVT-1402 at 600 mg met the primary ACR20 endpoint at Week 28 in Period 2 of the potentially registrational trial in difficult-to-treat rheumatoid arthritis, with 92.5% responding against 75.6% on placebo (p-value 0.0139). It is unlikely to advance IMVT-1402 further in Sjögren's disease beyond the ongoing, fully enrolled Phase 2 trial. Brepocitinib met the primary and all key secondary endpoints in the Phase 3 CLARITY-1 and CLARITY-2 trials in non-infectious uveitis. Priovant intends to file a supplemental New Drug Application in the first half of calendar 2027. Mosliciguat showed a placebo-adjusted reduction in pulmonary vascular resistance of -56.3% at Week 16 in the Phase 2 PHocus study in pulmonary hypertension associated with interstitial lung disease. The Phase 3 PHrontier study has started enrollment. Costs and cash. Research and development expenses fell to $145.7 million from $164.6 million a year earlier. Selling, general and administrative expenses rose to $154.1 million from $143.1 million, driven by the LISRAYA launch. Consolidated cash, cash equivalents and marketable securities were $4.2 billion as of September 30, 2026, including the Moderna payment received in July. In July, Genevant and Arbutus received $950 million from Moderna, the initial payment under a $2.25 billion patent infringement settlement. An additional $1.3 billion payment is contingent on a favorable resolution of Moderna's Section 1498 appeal. Roivant will hold an Investor Day in New York City and virtually on December 9, 2026.

Roivant Sciences Q2 earnings call highlights. November 9, 2026 Key points. * LISRAYA generated $31 million in initial revenue during roughly five weeks after its August approval, but specialty-pharmacy inventory stocking boosted the quarter and may be a modest headwind in December. Roivant reported a $153 million net loss from continuing operations. * Roivant's IMVT-1402 rheumatoid arthritis study met its primary endpoint: 92.5% of patients continuing the 600-milligram dose maintained an ACR20 response at week 28, versus about 75% on placebo. The company is discussing Phase 3 requirements with the FDA. * Roivant expects to seek approval for brepocitinib in noninfectious uveitis in 2027 and is enrolling patients in a Phase 3 mosliciguat study for pulmonary hypertension associated with interstitial lung disease. It also repurchased about $280 million of stock in the six months ended September 30. * Interested in Roivant Sciences? Here are five stocks we like better. Roivant Sciences NASDAQ: ROIV reported $31 million in net revenue from the initial launch of LISRAYA and said an experimental rheumatoid arthritis treatment met its primary endpoint in a randomized withdrawal study. Chief Executive Officer Matt Gline said the LISRAYA revenue covered roughly five weeks following the drug's August approval for dermatomyositis. He cautioned that the result benefited from specialty pharmacies purchasing inventory that had not yet been dispensed to patients by the end of the quarter. Roivant recorded a net loss from continuing operations of $153 million for the quarter ended September 30, 2026. On a non-GAAP basis, the loss was $133 million. LISRAYA launch and inventory. Gline said hundreds of patients were receiving paid LISRAYA at the end of September and that the number had grown to "many hundreds" by the time of the call. The company also had many hundreds of prescribers, he said. Roivant recognizes revenue when specialty pharmacies purchase the drug. A "meaningful amount" remained undispensed at September 30, but all of that inventory had subsequently been dispensed, Gline said. He declined to quantify the inventory or say what share of quarterly revenue it represented. Gline said the initial stocking likely provided a tailwind to the September quarter and could create a modest headwind in the December quarter. He expected inventory effects to become less relevant next year. Early payer access had generally been straightforward, although coverage restrictions varied among plans, Gline said. Prescribers were using LISRAYA across a broad range of patients, including some switching from off-label JAK inhibitors, intravenous immunoglobulin, steroids or immunosuppressants, as well as some newly diagnosed patients. Rheumatoid arthritis study meets primary endpoint. Roivant also reported results from the second period of a study of IMVT-1402 in difficult-to-treat rheumatoid arthritis. Participants had previously failed conventional treatment and at least two mechanisms of advanced therapy. In the first period, all patients received a 600-milligram dose. Those who achieved an ACR20 response - a measure of improvement in rheumatoid arthritis signs and symptoms - were then randomized to continue that dose, move to 300 milligrams or receive placebo. Discover more MarketBeat All Access MarketBeat Portfolio Tracker MarketBeat Research Tools At week 28, 92.5% of patients continuing the 600-milligram dose maintained an ACR20 response, compared with approximately 75% on placebo, Gline said. The primary endpoint achieved statistical significance. The 300-milligram group performed similarly to placebo, he said. For the more stringent ACR50 measure, 80% of patients on the higher dose had a response at week 28, compared with 56% on placebo. Gline said the result achieved a nominal p-value. Safety findings were consistent with prior disclosures, with event rates comparable to placebo and no new safety signals, he said. Gline said discussions with the Food and Drug Administration about the next trial are ongoing. Roivant does not yet know whether one Phase 3 study would be sufficient for approval or what endpoint regulators would require. He said an update on trial plans could come later this year or early next year. Other pipeline updates. Roivant is unlikely to advance IMVT-1402 further in Sjögren's disease, Gline said, citing developments involving competing treatments. The company plans to complete its Phase 2 study and assess the findings. He also reiterated that the company had not succeeded in cutaneous lupus erythematosus. Gline reviewed previously reported results for brepocitinib in noninfectious uveitis. He said the CLARITY studies met their primary and secondary endpoints, with nearly two-thirds of patients achieving steroid-free quiescence. Roivant expects to file a supplemental new drug application for the indication in 2027. For mosliciguat in pulmonary hypertension associated with interstitial lung disease, Gline highlighted a previously reported 56% placebo-adjusted reduction in pulmonary vascular resistance and a statistically significant 35-meter improvement in the six-minute walk test at week 16. A Phase 3 study is screening and enrolling patients, he said. The company is considering additional mosliciguat studies in other indications, but Gline did not commit to specific trials. Roivant also expects 2027 data for IMVT-1402 in Graves' disease and myasthenia gravis. Enrollment in the Graves' study has been strong, he said, without providing a more precise readout date. During the six months ended September 30, Roivant repurchased approximately $280 million of stock, or about 9.4 million shares. The company plans to discuss its commercial opportunities and pipeline further at its December 9 investor day. About Roivant Sciences (NASDAQ:ROIV). Roivant Sciences is a biopharmaceutical company that develops medicines through a network of subsidiary companies, which it calls "Vants." These businesses focus on advancing drug candidates in areas such as immunology, oncology, neuroscience and rare diseases. Founded in 2014, Roivant has built and supported subsidiaries to develop treatments, manage clinical programs and pursue partnerships. Its portfolio has included both internally developed candidates and medicines licensed from other companies. Roivant operates internationally, with activities spanning the United States and other markets. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Roivant Sciences, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list. While Roivant Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets. Continue following MarketBeat

Roivant Sciences (ROIV) set to announce quarterly earnings on Monday. Roivant Sciences (NASDAQ:ROIV - Get Free Report) is expected to post its Q2 2027 results before the market opens on Monday, November 9th. Analysts expect Roivant Sciences to post earnings of ($0.3666) per share and revenue of $4.14 million for the quarter. Investors are encouraged to explore the company's upcoming Q2 2027 earnings results page for the latest details on the call scheduled for Monday, November 9, 2026 at 8:00 AM ET. Roivant Sciences (NASDAQ:ROIV - Get Free Report) last released its earnings results on Friday, August 7th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.04. Roivant Sciences had a negative net margin of 3,534.96% and a negative return on equity of 22.94%. The firm had revenue of $1.44 million for the quarter, compared to the consensus estimate of $2.06 million. On average, analysts expect Roivant Sciences to post ($2.00) EPS for the current fiscal year and ($2.23) EPS for the next fiscal year. Roivant Sciences stock performance. Shares of NASDAQ:ROIV opened at $36.91 on Monday. The firm has a market cap of $26.66 billion, a price-to-earnings ratio of -69.64 and a beta of 1.23. The firm has a fifty day moving average price of $36.65 and a 200 day moving average price of $31.46. Roivant Sciences has a fifty-two week low of $19.30 and a fifty-two week high of $42.50. Insider activity. In other news, insider Mayukh Sukhatme sold 144,756 shares of the firm's stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $36.48, for a total value of $5,280,698.88. Following the completion of the sale, the insider directly owned 18,630,739 shares of the company's stock, valued at $679,649,358.72. This trade represents a 0.77% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Melissa Epperly sold 17,750 shares of Roivant Sciences stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $36.10, for a total transaction of $640,775.00. Following the transaction, the director directly owned 14,954 shares of the company's stock, valued at $539,839.40. The trade was a 54.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 1,822,688 shares of company stock worth $66,176,636. 8.80% of the stock is currently owned by corporate insiders. Analyst ratings changes. Several equities research analysts have recently issued reports on the company. Guggenheim lifted their target price on Roivant Sciences from $42.00 to $46.00 and gave the stock a "buy" rating in a report on Wednesday, September 9th. HC Wainwright raised their price target on Roivant Sciences from $41.00 to $47.00 and gave the company a "buy" rating in a report on Tuesday, September 8th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Roivant Sciences in a research note on Wednesday, August 19th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Roivant Sciences in a research note on Thursday, September 24th. Finally, Bank of America reaffirmed a "neutral" rating on shares of Roivant Sciences in a report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Roivant Sciences presently has a consensus rating of "Moderate Buy" and an average target price of $46.55. About Roivant Sciences. Roivant Sciences Ltd. (NASDAQ: ROIV) is a biopharmaceutical company focused on discovering, developing and commercializing medicines. The company organizes its activities through subsidiaries and partner companies, often referred to as "Vants," which specialize in particular therapeutic areas and stages of drug development. Roivant's research and development activities have included immunology, dermatology, women's health, rare diseases and other specialty-care fields. Its portfolio has included Vtama (tapinarof) cream, a nonsteroidal topical treatment approved in the United States for plaque psoriasis and atopic dermatitis. Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.